Effect of prior hypomethylating agent (HMA) use on clinical outcome of patients (Pts) with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndrome (MDS) when treated with standard induction chemotherapy (7+3)

Authors :: Mrinal M. Patnaik
Shahrukh K. Hashmi
Michelle A. Elliott
Muhanad Hreh
Salih Subari
William J. Hogan
Firas Baidoun
Mark R. Litzow
Aref Al-Kali
Source :: Journal of Clinical Oncology. 33:e18041-e18041
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e18041 Background: Pts with sAML arising from a prior MDS have poor prognosis. Anthracycline plus cytarabine (7+3) is a standard treatment option for pts who are fit for intensive therapy. However,...

Full Text Access

Tools